Literature DB >> 7128002

Dihydroergotoxine kinetics in healthy men after intravenous and oral administration.

B G Woodcock, W Loh, W D Habedank, N Rietbrock.   

Abstract

The kinetics of intravenous and oral dihydroergotoxine mesylate determined in eight healthy male subjects with a radioimmunoassay method incorporating a plasma extraction step to obtain maximal sensitivity and specificity. The intravenous plasma concentration-time curve showed an initial rapid decline (half-life[t1/2] = 3.5 min) and could be fitted to a three-compartment model. The high systemic clearance (20.2 to 28.8 ml x min-1 x kg-1) and large distribution volume, (9.9 to 20.41 x kg-1) were associated with a terminal t1/2 of 9.5 to 18.4 hr. The oral absorption was rapid. (t1/2 = 14.8 min). Absolute bioavailability was 5.3% to 12.4%. The terminal t1/2 and bioavailability were considerably lower than earlier estimates and this can be attributed to the use in these investigations of a more sensitive and specific dihydroergotoxine assay method.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128002     DOI: 10.1038/clpt.1982.212

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Bioavailability of dihydroergosine in healthy volunteers.

Authors:  P Cvelbar; J Culig; Z Kopitar; A Lenardic; J U Smerkolj; M Zorz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

2.  Absorption kinetics of dihydroergotoxine following oral administration to man.

Authors:  B G Woodcock; N Rietbrock; W Loh; W D Habedank
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

3.  The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Authors:  P Dominiak; J Grevel; E Abisch; H Grobecker; H J Dennler; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.